CDK4 and diffuse large B-cell lymphoma: In this context, the frequent overexpression of CDK4/6 and their association with poor prognosis in diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) warrant further investigations on CDK4/6 inhibitors as potential therapeutic options for these patients (NCT01739309, NCT02414724) [142].